Costs and clinical consequences of suboptimal atrial fibrillation management

Steven N SinghDepartment of Cardiology, Veterans Affairs Medical Center, Washington, DC, USAAbstract: Atrial fibrillation (AF) places a considerable burden on the US health care system, society, and individual patients due to its associated morbidity, mortality, and reduced health-related quality of...

Full description

Bibliographic Details
Main Author: Singh SN
Format: Article
Language:English
Published: Dove Medical Press 2012-03-01
Series:ClinicoEconomics and Outcomes Research
Online Access:http://www.dovepress.com/costs-and-clinical-consequences-of-suboptimal-atrial-fibrillation-mana-a9569
id doaj-cef5e51f262d47b1a880809f409b3d61
record_format Article
spelling doaj-cef5e51f262d47b1a880809f409b3d612020-11-24T21:08:07ZengDove Medical PressClinicoEconomics and Outcomes Research1178-69812012-03-012012default7990Costs and clinical consequences of suboptimal atrial fibrillation managementSingh SNSteven N SinghDepartment of Cardiology, Veterans Affairs Medical Center, Washington, DC, USAAbstract: Atrial fibrillation (AF) places a considerable burden on the US health care system, society, and individual patients due to its associated morbidity, mortality, and reduced health-related quality of life. AF increases the risk of stroke, which often results in lengthy hospital stays, increased disability, and long-term care, all of which impact medical costs. An expected increase in the prevalence of AF and incidence of AF-related stroke underscores the need for optimal management of this disorder. Although AF treatment strategies have been proven effective in clinical trials, data show that patients still receive suboptimal treatment. Adherence to AF treatment guidelines will help to optimize treatment and reduce costs due to AF-associated events; new treatments for AF show promise for future reductions in disease and cost burden due to improved tolerability profiles. Additional research is necessary to compare treatment costs and outcomes of new versus existing agents; an immediate effort to optimize treatment based on existing evidence and guidelines is critical to reducing the burden of AF.Keywords: atrial fibrillation, pharmacoeconomics, stroke, health-related quality of lifehttp://www.dovepress.com/costs-and-clinical-consequences-of-suboptimal-atrial-fibrillation-mana-a9569
collection DOAJ
language English
format Article
sources DOAJ
author Singh SN
spellingShingle Singh SN
Costs and clinical consequences of suboptimal atrial fibrillation management
ClinicoEconomics and Outcomes Research
author_facet Singh SN
author_sort Singh SN
title Costs and clinical consequences of suboptimal atrial fibrillation management
title_short Costs and clinical consequences of suboptimal atrial fibrillation management
title_full Costs and clinical consequences of suboptimal atrial fibrillation management
title_fullStr Costs and clinical consequences of suboptimal atrial fibrillation management
title_full_unstemmed Costs and clinical consequences of suboptimal atrial fibrillation management
title_sort costs and clinical consequences of suboptimal atrial fibrillation management
publisher Dove Medical Press
series ClinicoEconomics and Outcomes Research
issn 1178-6981
publishDate 2012-03-01
description Steven N SinghDepartment of Cardiology, Veterans Affairs Medical Center, Washington, DC, USAAbstract: Atrial fibrillation (AF) places a considerable burden on the US health care system, society, and individual patients due to its associated morbidity, mortality, and reduced health-related quality of life. AF increases the risk of stroke, which often results in lengthy hospital stays, increased disability, and long-term care, all of which impact medical costs. An expected increase in the prevalence of AF and incidence of AF-related stroke underscores the need for optimal management of this disorder. Although AF treatment strategies have been proven effective in clinical trials, data show that patients still receive suboptimal treatment. Adherence to AF treatment guidelines will help to optimize treatment and reduce costs due to AF-associated events; new treatments for AF show promise for future reductions in disease and cost burden due to improved tolerability profiles. Additional research is necessary to compare treatment costs and outcomes of new versus existing agents; an immediate effort to optimize treatment based on existing evidence and guidelines is critical to reducing the burden of AF.Keywords: atrial fibrillation, pharmacoeconomics, stroke, health-related quality of life
url http://www.dovepress.com/costs-and-clinical-consequences-of-suboptimal-atrial-fibrillation-mana-a9569
work_keys_str_mv AT singhsn costsandclinicalconsequencesofsuboptimalatrialfibrillationmanagement
_version_ 1716760779612487680